Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancer

BACKGROUND: Use of gonadotropin-releasing hormone (GnRH) agonists has become popular for virtually all stages of prostate cancer. We hypothesized that some men receive these agents after only a limited work-up for their cancer. Such cases may be missed by tumor registries, leading to underestimates...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Yong-fang, Goodwin, James S, Shahinian, Vahakn B
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2483971/
https://www.ncbi.nlm.nih.gov/pubmed/18620606
http://dx.doi.org/10.1186/1472-6963-8-146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2483971/
https://www.ncbi.nlm.nih.gov/pubmed/18620606
http://dx.doi.org/10.1186/1472-6963-8-146

Ejemplares similares